Introduction
The antinociceptive and antiinflammatory activities of 1,2-diaryl heterocyclics by cyclooxygenase-2 (COX-2) inhibition have been known since the 1970s [1] [2] [3] [4] . Since then, extensive research in this area has been carried out, and numerous compounds have been synthesized in a search for COX-2 inhibitory, antinociceptive and antiinflammatory activities. Two of these compounds, namely celecoxib I and rofecoxib II (Figure 1 ), have been employed clinically. However, these drugs have been found to have serious side effects on the heart. The heterocyclic residue of these compounds may be five-or six-membered, such as furan, thiophene, pyrrole, oxazole, thiazole, imidazole, pyrazole, pyridine, pyrimidine, etc. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The pyrazolones, especially antipyrine (1-aryl-2, 3-dimethyl-3-pyrazoline-4-one) derivatives, are well known for their antinociceptive and antipyretic activities and have been used widely in the clinic 21 . In light of the above findings, it appears that both 1,2-diarylheterocyclic and antipyrine residues are two important active pharmacophoric structures for antinociceptive activity. Besides, it has been well documented that 1,2-diaryl heterocyclic compounds have cytotoxic activity as a result of COX-2 inhibition 1, [22] [23] [24] [25] [26] .
In the present study, we have aimed to incorporate 1, 5-diarylimidazole and antipyrine residues in a single molecule and investigate antinociceptive and anticancer activities of the resultant compounds.
http://www.informahealthcare.com/enz were uncorrected. Spectroscopic data were recorded on the following instruments: FTIR (Fourier transform infrared), Shimadzu 8400S spectrophotometer; 1 H-NMR (nuclear magnetic resonance), Bruker 500 NMR spectrometer. Analyses for C, H, and N were within 0.4% of the theoretical values.
4-(2-Chloroacetyl-1-phenyl-2,3-dimethyl-3-pyrazoline-5--one 27 and 2-mercapto-1,5-diarylimidazoles 28 were prepared according to the literature methods. Some characteristics of the compounds are given in Table 1 .
General methods for preparation of 4-(1, 5-diarylimidazol-2-yl)thioacetyl-1-phenyl-2, 3-dimethyl-3-pyrazoline-5-one derivatives A mixture of 4-(2-chloroacetyl-1-phenyl-2,3-dimethyl-3-pyrazoline-5-one (5 mmol, 1.32 g), the appropriate 2-mercapto-1,5-diarylimidazole derivative (5.5 mmol), and K 2 CO 3 (6 mmol, 0.83 g) in acetone was refluxed for 8 h. 
Pharmacology

Animals
All the animals were housed in cages with free access to food and water. They were placed in a quiet and temperature-humidity controlled room (22 ± 2°C and 60 ± 5%, respectively) in which a 12:12 light-dark cycle was maintained. Mice (25-30 g) of either sex were used in the experiments. The animals were divided into 13 groups. Seven or eight animals were used in each study group. The mice were allowed 1-2 h to adjust to the laboratory conditions. All compounds were given intraperitoneally (i.p.) at 100 mg/kg doses. The control animals received 0.1 mL dimethylsulfoxide (DMSO) i.p. Morphine sulfate (5 mg/kg) and dipyrone (100 mg/kg) were used as the reference antinociceptive agents. The study was approved by the Local Ethics Committee of Osmangazi University, Medical School, Eskisehir, Turkey.
Tail clip test
A pressure-standardized artery clip was applied 3-4 cm from the tip of the tail for evaluation of the response to noxious pressure. Turning toward or biting at the clip within 15 s of artery clip placement was the threshold used in this test 29 .
Hot-plate test
The test was based on that described by Eddy and Leimbach. A transparent glass cylinder ( 16 cm high, 16 cm diameter) was used to keep the mouse on the heated surface of the plate. The temperature of the hot-plate was set to 55 ± 0.5°C by using a thermoregulated water-circulating pump. The time of latency was defined as the time period between the zero point when the animal was placed on the hot-plate surface and the time when the animal licked its paw or jumped off to avoid thermal pain (cutoff time 30 s) [30] [31] [32] .
Abdominal constriction test
This test was performed by the i.p. injection of 0.6% acetic acid (60 mg/kg). The number of stretching movements (arching of back, development of tension in the abdominal muscles, elongation of the body, and extension of the forelimbs) was observed. Stretching movements commenced 5 min after acetic acid injection. These contractions were counted and recorded for 10 min. Antinociceptive activity was expressed as the reduction in the number of abdominal constrictions 33 . protocol was followed and a sulforhodamine B (SRB) protein assay was used to estimate cell viability of growth 34 .
Anticancer activity test
Results and discussion
Chemistry
The syntheses of the title 4-(1,5-diarylimidazol-2-yl) thioacetyl-1-phenyl-2,3-dimethyl-3-pyrazoline-5-one derivatives 2a-l were accomplished in accordance with the sequence of reaction depicted in Scheme 1. The starting materials, 1,5-diaryl-2-mercaptoimidazoles 1a-l, were prepared by reacting the appropriate 2-amino-49-substituted acetophenones and 4-substituted phenylisothiocyanates in pyridine according to the method described in the literature 28 . To obtain the final products 2a-l, 4-(2-chloroacetyl-1-phenyl-2,3-dimethyl-3-pyrazoline-5-one was reacted with suitable imidazole derivatives 1a-l under Williamson ether synthesis conditions. The structures of the obtained compounds were elucidated using spectral data. In the IR spectra, the charactesistic amide and ketone carbonyl functions were observed in the 1672-1652 cm −1 region separately or as a single band 35 . The NMR spectra of the compounds 2a-l exhibited singlets resulting from resonances of the thioacetyl-1-phenyl-2,3-dimethyl-3-pyrazoline-5-one residue assigned to C-CH 3 protons at 2.58 ppm, to N-CH 3 protons at 3.34-3.36 ppm, and to S-CH 2 -CO protons at 4.45-4.49 ppm, respectively. The other common proton groups existing in all compounds, imidazole-C 4 -H protons, were obtained as singlets at 7.26-7.29 ppm for some of the compounds. For the others, the mentioned protons were taking part in multiplets because of overlaping with aromatic protons.
Antinociceptive activity
Antinociceptive activities of the compounds were determined by using the tail clip test, hot-plate test, and abdominal constriction test. Both the tail clip and hot-plate tests were used to evaluate central antinociceptive activity and the abdominal constriction test was used to assess peripheral antinociceptive activity. The findings are shown in Table 2 and all data were compared to control groups. The results are given as a percentage of the maximal possible effect (%MPE ± SEM), which is defined by following equation: %MPE = [(postdrug latency) (predrug latency) /(cutoff time − ) ) (predrug latency)] 100 − × Statistical analyses were carried out using Student's t-test. Compounds 2a, 2d, and 2g exhibited antinociceptive activity in the tail clip test. 2a and 2d showed greater antinociceptive activities than the reference compounds. The other compounds did not display any significant antinociceptive activity in this test.
In the hot-plate test, only compound 2d evoked antinociceptive activity when compared with the control group or dipyrone. On the other hand, the other compounds did not exhibit any antinociceptive activity when compared with control or reference compounds.
In the abdominal constriction test, although all the compounds exhibited significant antinociceptive activities, compounds 2d and 2j especially were found to produce the most antinociceptive activity at the dose tested. Compound 2d was antinociceptive when compared with dipyrone (p ≤ 0.05), and at 100 mg/kg it produced antinociceptive activity equivalent to that of morphine. 2a was the only compound not to show antinociceptive activity in the abdominal constriction test.
Thus, in the present study, it was found that compound 2d was the most active molecule in all antinociceptive tests. Therefore, this compound was thought to produce both The compound 2d bears a fluoro group on one of the aryl residues. The other active molecules 2g and 2j bear a methyl and a methoxy on each of the other aryl residues while 2a is nonsubstituted. Although it is known that the mentioned substituents are important for the antinociceptive activity of 1,2-diarylheterocyclic compounds 1 , it may not be possible to put forward an idea about the contribution of the substituent to the activity.
Anticancer activity
The compounds selected by NCI and their preliminary anticancer test results as growth percent values obtained against NSCLC (non-small cell lung cancer), BC (breast cancer), and CNSC (central nervous system cancer) cells are given in Table 3 . These cells were NCI-H460, MCF7, and SF-268, respectively. Compound 2i showed remarkable inhibition values for the cells NCI-H460 and MCF7, but the other compounds were found to be inactive. Compound 2i was accepted for a further screening test. In this step, the selected compound was evaluated in vitro against 66 human tumor cell lines derived from nine neoplastic diseases. The detailed test results are given in Table 4 .
According to the test method, it is stated that compounds having growth percent values greater than −4 are considered as inactive. It can be seen that for compound 2i, log 10 GI 50 (logarithm of concentration that causes 50% growth inhibition) values are smaller than −4. Therefore, we may conclude that the compound provides a notable activity level. Melphalan and cisplatin (cis-diaminodichloroplatinum), two commonly used chemotherapeutic agents, were used as standard compounds. When the mean-graph midpoint (MG-MID) values of the compounds melphalan and cisplatin, i.e. −5.09 and −6.20 respectively, are considered, it is observed that compound 2i provides an acceptable activity level (MG-MID −4.39). 
